Thanks to good sales performance in Healthcare and Electronics, Group sales in the second quarter of 2024 rose by 1.7% organically. Overall, Group sales rose by 0.9% to €5,352 million.

EBITDA was down organically by 0.8% to €1.5 billion, against a high basis of comparison.

'Healthcare and Electronics recorded organic sales growth. AI semiconductor materials market reaches inflection point. Process Solutions order intake continues to improve sequentially and year-on-year', says the Group.

Merck raises its targets for 2024 and for the Healthcare and Electronics business sectors. The Group expects net sales in the range of €20.7 to €22.1 billion and organic growth of +2% to +5% (previously: €20.6 to €22.1 billion; organic growth of +1% to +5%).

EBITDA should be in the range of 5.8 to 6.4 billion euros, with organic growth of +4% to +10% (previously: 5.7 to 6.3 billion euros; organic growth of +1% to +7%). EPS is now expected to be between E8.20 and E9.30 (previously: E8.05 to E9.10).

Copyright (c) 2024 CercleFinance.com. All rights reserved.